Keros Therapeutics (NASDAQ:KROS) Now Covered by Jefferies Financial Group

Jefferies Financial Group assumed coverage on shares of Keros Therapeutics (NASDAQ:KROS) in a report issued on Tuesday morning, MarketBeat reports. The brokerage issued a buy rating on the stock.

Other equities research analysts have also issued research reports about the stock. Guggenheim initiated coverage on shares of Keros Therapeutics in a research note on Monday, September 23rd. They issued a “buy” rating and a $96.00 price objective for the company. Cantor Fitzgerald initiated coverage on Keros Therapeutics in a report on Thursday, October 24th. They set an “overweight” rating on the stock. Bank of America reduced their price objective on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research note on Thursday, September 12th. Finally, Scotiabank began coverage on Keros Therapeutics in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 target price on the stock. Twelve analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $88.89.

Keros Therapeutics Stock Up 1.1 %

Shares of Keros Therapeutics stock opened at $67.91 on Tuesday. The business has a 50-day simple moving average of $57.74 and a 200 day simple moving average of $52.10. Keros Therapeutics has a one year low of $27.31 and a one year high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The business had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 45.13%. The company’s quarterly revenue was up 4750.0% on a year-over-year basis. During the same quarter last year, the business earned ($1.33) earnings per share. Research analysts anticipate that Keros Therapeutics will post -4.93 EPS for the current year.

Insider Activity at Keros Therapeutics

In related news, Director Carl L. Gordon sold 250,000 shares of Keros Therapeutics stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total value of $11,002,500.00. Following the completion of the sale, the director now directly owns 119,522 shares in the company, valued at approximately $5,260,163.22. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 22.90% of the stock is currently owned by insiders.

Institutional Trading of Keros Therapeutics

Large investors have recently added to or reduced their stakes in the business. KBC Group NV increased its holdings in Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after acquiring an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after purchasing an additional 280 shares during the period. Values First Advisors Inc. purchased a new stake in shares of Keros Therapeutics in the third quarter worth $89,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Keros Therapeutics during the 2nd quarter valued at $128,000. Finally, Ameritas Investment Partners Inc. lifted its stake in shares of Keros Therapeutics by 14.5% during the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock valued at $169,000 after buying an additional 324 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.